tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

GANX Stock Latest News

Gain Therapeutics Unveils New Parkinson’s Treatment Data
Company AnnouncementsGain Therapeutics Unveils New Parkinson’s Treatment Data
8h ago
8K
GANX
Gain Therapeutics presents additional data on study of GT-02287
PremiumThe Fly
Gain Therapeutics presents additional data on study of GT-02287
18h ago
GANX
Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
PremiumRatings
Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position
14d ago
GANX
Gain Therapeutics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Gain Therapeutics Reports 2024 Financial Results and Progress
14d ago
GANX
Gain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
PremiumThe Fly
Gain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
15d ago
GANX
Gain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
PremiumThe FlyGain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
15d ago
GANX
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
Premium
Ratings
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
23d ago
GANX
GANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
GANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
24d ago
GANX
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
PremiumRatings
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
25d ago
GANX
Gain Therapeutics doses first participant in Phase 1b trial of GT-02287
PremiumThe Fly
Gain Therapeutics doses first participant in Phase 1b trial of GT-02287
28d ago
GANX
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
PremiumThe Fly
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
1M ago
W
AL
Gain Therapeutics initiated with an Outperform at Scotiabank
PremiumThe Fly
Gain Therapeutics initiated with an Outperform at Scotiabank
1M ago
GANX
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
PremiumCompany AnnouncementsGain Therapeutics Advances GT-02287 in Parkinson’s Trials
2M ago
8K
GANX
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
Premium
The Fly
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
2M ago
GANX
Gain Therapeutics announces formation of clinical advisory board
Premium
The Fly
Gain Therapeutics announces formation of clinical advisory board
3M ago
GANX
Gain Therapeutics Appoints New CEO Amidst Clinical Progress
PremiumCompany Announcements
Gain Therapeutics Appoints New CEO Amidst Clinical Progress
3M ago
8K
GANX
Gain Therapeutics appoints Mack as CEO, Director
PremiumThe Fly
Gain Therapeutics appoints Mack as CEO, Director
3M ago
GANX
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM
PremiumThe Fly
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM
4M ago
GANX
Gain Therapeutics Advances GT-02287 into Phase 1b Trial
PremiumCompany Announcements
Gain Therapeutics Advances GT-02287 into Phase 1b Trial
4M ago
8K
GANX
Gain Therapeutics initiates Phase 1b trial of GT-02287
PremiumThe FlyGain Therapeutics initiates Phase 1b trial of GT-02287
4M ago
GANX
Gain initiated with Buy on Parkison’s potential at Roth MKM
Premium
The Fly
Gain initiated with Buy on Parkison’s potential at Roth MKM
4M ago
GANX
Gain Therapeutics initiated with a Buy at Roth MKM
Premium
The Fly
Gain Therapeutics initiated with a Buy at Roth MKM
4M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >